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Abstract
Background: Depressive symptoms are common in patients with first episode psychosis (FEP) and have serious
consequences for them. The main aims of this study were to examine the course of depression in FEP patients and
explore whether any patient characteristics at baseline predicts depressive symptoms after one year.
Method: A total of 198 FEP patients with schizophrenia spectrum disorders were assessed for depressive symptoms
with Calgary Depression Scale for Schizophrenia (CDSS) at baseline and 127 were followed for one year. A CDSS
score [greater than or equal to] 6 was used as a cut-off score for depression.
Results: Approximately 50% of the patients were depressed (CDSS[greater than or equal to]6) at baseline. At
follow-up approximately 35% had depression. The course of depressive symptoms varied, 26% was depressed at
both baseline and follow-up, 9% became depressed during the follow-up, 22% remitted from depression during
the 12 months and 43% was neither depressed at baseline nor at follow-up. Poor childhood social functioning,
long duration of untreated psychosis (DUP) and depressive symptoms at baseline predicted depression at
12 months follow-up.
Conclusion: Depressive symptoms are frequent in the first year after onset of psychosis. Patients with poor social
functioning in childhood, long DUP and depressive symptoms at baseline are more prone to have depressive
symptoms after one year. These patients should be identified and proper treatment provided.
Background
Depressive symptoms are common in patients with a first
episode psychosis (FEP) with a reported prevalence from
17% to 83% in the different studies [1-4]. This wide vari-
ation in prevalence may be due to heterogeneity in the
study population, variation of assessment tools and the
study’s definition of depression. Depressive symptoms
occur in different phases of the psychosis, including pro-
dromal [5,6], acute [7] and post-psychotic phases [8,9].
They have thus been regarded as intrinsic to schizophre-
nia psychopathology, similar to positive, negative, and dis-
organized symptom clusters [10].
There are only few studies examining the course and
development of depressive symptoms in patients with a
FEP. This is important as there is an increased risk of
suicide during the early phases of psychotic illness
[11,12]. Furthermore, knowledge about the course of de-
pressive symptoms may facilitate earlier identification of
patients who are prone to develop a severe course. In
line with this, Cotton and coworkers [13] emphasized
the need for prospective studies mapping the trajectory
of depressive symptoms in psychotic disorders to pro-
vide a critical step towards developing a clear under-
standing of the phenomenology of depressive pathology
in the early phases of psychotic disorders.
To our knowledge only five studies have explored the
course of depression in FEP over time; and two of these
were acute treatment outcome studies which only ex-
plored the course of depressive symptoms from admis-
sion to discharge (between 39 and 56 days) [3,14]. Riedel
and colleagues [14] found that depressed first-episode
schizophrenia patients scored significantly higher on all
PANSS subscales (PANSS total, PANSS positive and
PANSS negative) both at admission and discharge. How-
ever, Bottlender and coworkers [3] found that depressive
symptoms in the acute psychotic phase was a positive
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prognostic indicator for patients concerning negative
symptoms.
Oosthuizen and coworkers [15] assessed changes in
depressive symptoms over a two-years period. They
found that depressive symptoms experienced during an
acute psychotic episode were different from those expe-
rienced in the post-psychotic period. Acute depressive
symptoms were related to psychotic symptoms, and
these symptoms improved when the psychotic symptoms
resolved in response to antipsychotic treatment. Depres-
sive symptoms observed in the post-psychotic period
were referred to as ‘persistent depressive symptoms’, be-
cause they were not responsive to antipsychotic therapy
alone.
Cotton and colleagues [13] aimed to determine if there
were differences in the clinical and functional character-
istics of FEP patients with and without depressive symp-
toms during an18 months early intervention treatment
program [16]. The group with depressive symptoms at
baseline was less hospitalized and had less substance
abuse during treatment. At discharge patients in this
group were also more likely to be depressed and had
better insight concerning their illness. The depressed
group of patients was also significantly more likely to
have a past diagnosis of personality disorder, suicide at-
tempts, a shorter duration of treatment, ongoing sub-
stance abuse, lower GAF mean score and were less likely
to be working.
Upthegrove and colleagues [17] examined prospect-
ively the course of depression in prodromal, acute, and
12 months follow-up period of psychosis. Including a
total of 82 patients, they found that prodromal depres-
sion was significantly linked with the development of de-
pression in the acute and follow-up phases, and acute
depression was also significantly related with the devel-
opment of later depression. Severity of depression was
not significantly correlated with the severity of positive
and negative symptoms in the acute or follow-up phases.
As seen from this review there is a need for a wider and
more elaborated examination of the association between
the course of depressive symptoms, patient characteristics
and outcome.
In the present study we examined the course of de-
pressive symptoms during a 12 month follow-up
period.
We aimed to answer the following questions:
1. How many FEP patients are scored as depressed
measured by CDSS (CDSS ≥ 6) at baseline and at
12 months follow-up?
2. Is it possible to identify subgroups of patients with
different profiles of depressive symptoms during a
one-year follow-up period, and can these subgroups
be differentiated on demographic characteristics
such as DUP, premorbid functioning (PAS) and
clinical characteristics (PANSS scores)?
3. To what extent are there any differences in
suicidality, between these groups?
4. To what extent do patient characteristics at baseline
predict 12 months CDSS scores?
Method
Subjects
A total of 198 patients with a first episode psychosis
(FEP) were included at baseline from the ongoing The-
matically Organized Psychosis Research (TOP) study at
the Oslo University Hospital and University of Oslo,
Norway. Of these, a total of 127 patients were followed
for one year. Romm and colleagues have previously
reported the baseline characteristics of 119 of the 198
patients included in the present study [4]. The present
study is a further exploration of depressive symptoms in
a 12 months follow-up period.
These samples were included from March 2004 to
February 2010. The inclusion criteria were (1) age 18 to
65 years and a first episode non-affective psychosis
according to Diagnostic and Structural Manual of Men-
tal Disorders, fourth edition (DSM-IV) [18]. Exclusion
criteria were a history of organic brain disorder, a signifi-
cant comorbid medical condition, or an IQ below 70.
Inclusion was based on the time from the first onset of
positive psychotic symptoms (the first week with a
PANSS score of 4 or more on Positive Scale Items 1, 3,
5, 6 or General Scale item 9) to the start of first admis-
sion to the study [19]. Patients with previous treatment
with antipsychotic medication in adequate dosage for
more than 12 weeks were not considered as FEP
patients.
The study is approved by the Regional Committee for
Medical Research Ethics and the Norwegian Data In-
spectorate. A written informed consent was obtained
from all of the participants.
Clinical assessment and instruments
Diagnosis was set by the Structural Clinical Interview for
DSM-IV axis I disorders (SCID I) [18]. Current symptom
severity was assessed on the Positive and Negative Syn-
drome Scale (PANSS) [20] and characterized by five sub-
scales; positive, negative, excitative, depressive, and
cognitive [21]. Depression was assessed using the Cal-
gary Depression Scale for Schizophrenia (CDSS) [22].
CDSS has been shown to be reliable and valid and it
measures depression separate from negative or extrapyr-
amidal symptoms [23,24]. In a systematic review of in-
struments measuring depressive symptoms, the CDSS
outperformed other depression instruments in terms of
reliability and validity in patients with schizophrenia
[25]. The cut-off score for depression varies between
Sönmez et al. BMC Psychiatry 2013, 13:106 Page 2 of 9
http://www.biomedcentral.com/1471-244X/13/106
three and nine in the different studies [15,17,26-28]. We
chose to use a cut-off score of equal and/or above six, in
line with some of the previous studies [28-30]. Suicidality
was measured with the CDSS-suicide item. Premorbid
functioning was assessed with the Premorbid Adjustment
Scale (PAS) [31]. The premorbid phase is defined as the
time from birth until six months before onset of psychosis.
PAS measures social and academic functioning in 4 time
periods; childhood, early adolescence, late adolescence,
and adult life. We decided to focus on social and academic
functioning in childhood and early adolescence only. It
may be difficult to discern between premorbid and psych-
otic symptoms in late adolescence when the first psychotic
episode usually occur. General level of symptoms and
functioning was assessed with the Global Assessment of
Functioning scale (GAF), split version [32,33]. Problem
drinking was screened by the Alcohol Use Disorders Iden-
tification Test (AUDIT) [34], and use of illegal drugs was
assessed with Drug Use Disorders Identification Test
(DUDIT) [35]. DUP was measured following the criteria
described by Larsen et al. [36]. At 12-month follow-up the
participants were re-assessed with the following instru-
ments: GAF, PANSS, CDSS, AUDIT and DUDIT.
Reliability
Clinical interviews were carried out by trained psycholo-
gists and psychiatrists. The interviewers were all enrolled
in the general training and reliability program in the
TOP study. For DSM-IV diagnostics, mean overall kappa
with training videos was 0.77 (95% confidence interval
[CI]: 0.60-0.94). Interrater reliability, measured by the
interclass correlation coefficient (1.1), was for the PANSS
positive subscale 0.82 (95% CI: 0.66-0.94), for the PANSS
negative subscale 0.76 (95% CI: 0.58-093), the PANSS gen-
eral subscale 0.73 (95% CI: 0.54-0.90), the GAF symptom
scale 0.86 (95% CI: 0.77-0.92), and the GAF functioning
scale 0.85 (95% CI: 0.76-0.92).
Analysis
Statistical analysis was done by using SPSS for Windows
(version 16.0). Descriptive statistics was performed on
the whole sample to obtain the independent variables’
frequencies, means and standard deviations. To identify
different subgroups of patients with different trajectories
of depressive symptoms, we used a cut-off score above
or equal six on the CDSS. Based on the CDSS scores we
wanted to identify patients who were depressed in the
whole follow-up period, patients who were depressed at
baseline, but recovered during the follow-up period, pa-
tients who became depressed during the follow-up
period, and finally patients who never were scored as de-
pressed during the follow-up period. One-Way ANOVA
was performed in order to compare the means of the
follow-up subgroups. Bivariate correlations were used to
study the correlation of each independent variable with
CDSS total scores at both baseline and 12-month
follow-up.
DUP required transformation to its natural logarithm
(Ln[DUP + 1]).
Hierarchical multiple linear regression was used to as-
sess the ability of baseline variables to predict depression
(CDSS total score) at 12-month follow-up. The predic-
tors were selected based on theoretical considerations:
gender differences, neurocognitive developmental issues
(premorbid functioning in childhood), and basic psycho-
pathological/psychotic symptoms that may have associ-
ation with the development of depressive symptoms in
FEP. To estimate how much of the variance each of the
patient variables explained, we used a blockwise multiple
hierarchic regression analysis. Gender was entered in the
first block, because this variable must be considered as
the most basic one. PAS childhood social and academic
were entered in the second block as a measure of early
social and academic functioning. The duration of psych-
osis was entered in the third block. Finally, we entered
the five different PANSS subscales which we considered
as the most important variables in predicting depressive
symptoms at 12 months follow-up. By entering the
PANSS subscale scores in the fourth block, we con-
trolled for the amount of variance explained by the vari-
ables in the three first blocks.
Results
Table 1 displays the baseline characteristics of the pa-
tients. The mean age at baseline was 27.98 years, the
range was from 17 to 56, and 127 (64%) of the sample
were men. A total of 152 (77%) patients were European
(at least one parent), 34 were married/cohabited (17%),
118 (77%) had high school and 74 (37%) were working
or studying. A total of 60 (30%) patients lived alone and
57 (29%) were living with their parents. The diagnostic
distribution was as follows: schizophrenia 102 ( 51.5%),
schizophreniform disorder 17 ( 8.5%), schizoaffective
disorder 10 ( 5.0%), brief psychotic disorder 8 ( 4.0%),
delusional disorder 9 ( 4.5%), psychotic disorder not
otherwise specified 52 ( 26.5%).
A total of 96 (48.5%) patients had a score of CDSS ≥ 6
at baseline. At follow-up 44 (34.6%) patients had a score
above or equal six. The associations between these pa-
tients’ demographic and clinical characteristics and their
CDSS total score at baseline and at 12 months follow-up
are also presented in Table 1.
CDSS at baseline correlated significantly with GAF S,
PANSS excitative, PAS childhood social and academic,
PAS early adolescence social and academic, DUP, Insight
(PANSS g12) and AUDIT. Among the demographic vari-
ables there was only gender that correlated significantly
with CDSS-total at baseline (female most depressed). At
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12 months follow-up CDSS correlated significantly with
baseline GAF S and GAF F, PANSS negative and depres-
sive component, PAS childhood social and academic,
and PAS early adolescence social, and DUP.
The course of depressive symptoms during the 12
months period followed four different pathways:
Group 1) thirty-three patients (26%) were depressed at
both baseline and follow-up (G1; Persistent depres-
sion), Group 2) eleven patients (9%) had no depressive
symptoms at baseline, but developed depressive symp-
toms during the 12-months follow-up (G2; Depression
follow-up), Group 3) twenty-eight patients (22%) had
depressive symptoms at baseline and remitted during
the 12 months follow-up (G3; Depression baseline),
Group 4) fifty five patients (43%) had no depressive
symptoms neither at baseline nor at follow-up (G4; No
depression) (Table 2).
Table 2 shows the differences between the four
groups at baseline. As displayed, the Persistent depres-
sion group (G1) scored significantly different com-
pared to the group no depression. (G4) concerning
GAF S, PAS childhood social, academic and PAS early
adolescence social. Regarding CDSS suicide score at
baseline, G1 had significantly higher score than both
G2 and G4, and G3 had significantly higher suicidality
score than G2.
Table 3 displays the differences between the four
groups at 12 months follow-up. The most notable differ-
ence was, between G1 and G4. G1 had higher levels of
global symptoms (GAF S), poorer functioning (GAF F)
and more negative and excitative symptoms (PANSS
components). Regarding CDSS suicide score, G1 had
significantly higher score at follow-up than all the other
three subgroups.
Table 1 Mean and SD of patients’ demographic and clinical baseline characteristics and their correlations with CDSS
total scores at baseline (n = 198) and 12-month follow-up (n = 127)
Mean (SD) Correlation With CDSS total
score at baseline (Pearson)
Correlation with CDSS total score
at12-month follow-up (Pearson)
Age 27.98 (8.70) 0.01 0.10
Gender (M) N = 127 (64%) 0.18* 0.13
Education (year) 12.71 (2.93) −0.02 −0.13
GAF symptom 41.12 (11.38) −0.29** −0.26**
GAF function 44.14 (12.65) −0.11 −0.22*
PANSS positive 12.95 (4.49) 0.07 0.06
PANSS negative 20.13 (7.72) 0.11 0.18*
PANSS excitative 8.07 (2.84) 0.21* −0.04
PANSS depressive 12.15 (3.61) 0.58** 0.37**
PANSS cognitive 5.38 (2.07) −0.004 0.06
PANSS-total score 63.38 (15.00) 0.27** 0.23*
PAS childhood social 2.51 (3.05) 0.26** 0.32**
PAS childhood academic 3.45 (2.43) 0.26** 0.26**
PAS early adolescence social 2.69 (2.88) 0.21** 0.22*
PAS early adolesc. academic 4.26 (2.75) 0.24* 0.17
DUPln 1.63 (0.80) 0.23** 0.30**
Insight (PANSS G12) 2.76 (1.36) −0.18* −0.11
AUDIT 7.76 (7.70) 0.17* 0.09
DUDIT 6.36 (9.58) 0.10 0.03
Anti-depressive medication day dosis 37.50 (35.75) 0.05 0.03
Anti-psychotic medication, day dosis 97.17 (155.88) −0.05 −0.07
CDSS total baseline 6.23 (4.44) —————————————————— 0.48**
*Correlation is significant at the 0.05 level (2-tailed).
**Correlation is significant at the 0.01 level (2-tailed).
PANSS Positive and negative syndrome scale.
GAF Global assessment of functioning.
PAS Premorbid adjustment scale.
DUP Duration of untreated psychosis.
AUDIT Alcohol use disorders identification test.
DUDIT Drug use disorders identification test.
CDSS Calgary depression scale for schizophrenia.
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A blockwise multiple regression analysis was conducted
in order to detect possible variables at baseline that might
predict depressive symptoms at 12 months follow-up. The
included variables explained a total of 25% of the variance
in the level of depression as measured by the CDSS.
PAS childhood social, DUP, and PANSS depressive
symptoms explained a significant proportion of the
variance (Table 4).
Discussion
The present study showed that depressive symptoms are
frequent during the first year of treatment in FEP. Ap-
proximately half of the patients had depression at start of
treatment while more than one third were depressed at
one-year follow-up. In line with other studies [8,13,14,17]
the depressive symptoms decreased during the follow-up
period.
Furthermore, we detected four different trajectories of
depressive symptoms during a 12 months follow-up.
The four groups differed significantly as it comes to pa-
tient characteristics and clinical variables. The most not-
ably difference was between G1 (persistent depression)
and G4 (no depression). G1 scored significantly higher
on global symptoms in addition to premorbid adjust-
ments (PAS childhood social and academic score, and
PAS early adolescence social score) at baseline. At 12 months
follow-up the differences between the two groups were even
more pronounced. Most notably the group with persistent
depression scored poorer on GAF F, and the PANSS nega-
tive symptom scale.
Table 2 Comparison of the 4 subgroups regarding baseline variables
G1: Persistent
depression
G2: depression
follow-up
G3: depression
baseline
G4: No depression Significant
difference(s)
between;N = 33 N = 11 N = 28 N = 55
Gender (M) 18/55% 8/73% 15/54% 41/75%
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age 28.3 (8.71) 28.0 (5.90) 23.9 (5.00) 27.2 (7.81)
GAF symptom 37.58 (8.58) 39.36 (8.61) 38.93 (8.58) 45.31 (14.87) G1 and G4 (.034)
GAF function 40.24 (12.37) 43.00 (11.81) 42.39 (11.93) 47.53 (14.34)
PANSS Positive 13.52 (4.24) 13.45 (5.26) 13.61 (4.68) 12.76 (4.89)
PANSS Negative 21.83 (8.06) 21.36 (7.75) 21.93 (7.89) 18.78 (6.84)
PANSS Excitative 7.88 (1.90) 7.00 (2.10) 8.66 (2.94) 7.55 (2.41)
PANSS Depressive 14.79 (2.10) 13.55 (4.53) 12.96 (2.59) 9.89 (3.09) G1 and G4 (.000)
G2 and G4 (.003)
G3 and G4 (.000)
PANSS Cognitive 5.67 (2.16) 5.36 (2.16) 5.39 (1.93) 5.38 (1.87)
PANSS-total 68.50 (12.22) 65.91 (11.90) 67.78 (14.90) 58.56 (13.34) G1 and G4 (.013)
G3 and G4 (.038)
AUDIT 8.87 (8.63) 4.70 (7.45) 9.21 (5.63) 6.46 (7.53)
DUDIT 7.16 (11.18) 2.40 (4.60) 5.21 (8.59) 7.27 (10.03)
PAS Childhood social 4.09 (3.75) 2.36 (2.54) 1.96 (2.60) 1.69 (2.24) G1 and G4 (.003)
G1 and G3 (.038)
PAS Childhood academic 4.29 (2.44) 4.45 (3.21) 3.54 (2.76) 2.55 (1.92) G1 and G4 (.017)
PAS Early adolescence social 4.06 (3.55) 2.27 (2.57) 2.71 (2.68) 2.05 (2.44) G1 and G4 (.020)
PAS Early adolesc. academic 4.71 (2.83) 4.82 (3.06) 4.25 (3.04) 3.22 (2.30)
DUPin 4.17 (1.76) 3.86 (1.78) 3.44 (1.85) 3.35 (1.68)
CDSS-suicide .91 (.678) .18 (.405) .75 (.645) .11 (.315) G1 and G4 (.000)
G1 and G2 (.002)
G2 and G3 (.035)
PANSS Positive and negative syndrome scale.
GAF Global Assessment of Functioning.
PAS Premorbid adjustment scale.
DUP Duration of untreated psychosis.
AUDIT Alcohol use disorders identification test.
DUDIT Drug use disorders identification test.
CDSS Calgary depression scale for schizophrenia.
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As it comes to suicidality the group with persistent de-
pression (G1) was, as expected, more suicidal than the
other groups. However, there were also significant differ-
ences in level of suicidal thoughts at follow-up between
this group (G1) and the group with depression follow-up
(G2), in spite of the fact that they had equal levels of de-
pression. As shown in table three the PANSS depressive
component was almost the same between the two
groups.
Birchwood and colleagues [9] emphasized the need for
making clear distinctions between three core but not
mutually exclusive pathways to depression in schizo-
phrenia; a) depression that is intrinsic to the psychosis
diathesis, b) depression as a reaction to the psychotic
episode and c) depression as a product of disturbed de-
velopmental pathways resulting from developmental
trauma and the childhood antecedents of psychosis.
Based on the current findings, one could speculate that
the group with persistent depression (G1) corresponds to
the pathway that explain depressive symptoms in psych-
osis as intrinsic to the psychosis diathesis [9]. This type
of depression is seen as an essential aspect of the schizo-
phrenic process being an artefact of negative symptoms
and Parkinsonism in a limited subgroup of patients
whom these symptoms are particularly severe [37]. Ac-
cordingly, G1 had the highest PANSS-negative score and
significantly higher score than the G4’s PANSS-negative
score.
Table 3 Comparison of the 4 subgroups regarding 12 months follow up variables
G1: Persistent depression G2: Depression follow-up G3: Depression baseline G4: No depression Significant
difference(s)
between;
N = 33 N = 11 N = 28 N = 55
Gender (M) 18/54% 8/73% 15/54% 41/75%
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age 28.33 (8.71) 28.00 (5.90) 23.86 (5.00) 27.20 (7.81)
GAF symptom 40.21 (10.45) 40.45 (10.37) 58.52 (15.66) 54.36 (17.10) G1 and G4 (.001)
G1 and G3 (.000)
G2 and G4 (.049)
G2 and G3 (.011)
GAF function 42.42 (11.22) 43.82 (13.35) 57.48 (15.58) 56.60 (16.07) G1 and G4 (.000)
G1 and G3 (.002)
PANSS Positive 12.65 (4.74) 13.64 (6.03) 9.24 (3.97) 10.42 (5.57)
PANSS Negative 21.24 (7.12) 19.73 (7.39) 16.71 (6.31) 16.57 (5.54) G1 and G4 (.013)
PANSS Excitative 7.76 (2.56) 7.18 (2.44) 6.54 (1.67) 6.46 (2.02) G1 and G4 (.064)
PANSS Depressive 13.70 (3.11) 13.64 (3.38) 8.29 (2.21) 8.74 (3.15) G1 and G4 (.000)
G1 and G3 (.000)
G2 and G4 (.000)
G2 and G3 (.000)
PANSS Cognitive 5.61 (2.51) 5.82 (1.54) 4.93 (2.28) 4.93 (2.03)
PANSS-total 65.82 (13.29) 64.36 (12.21) 49.11 (12.08) 50.67 (13.76) G1 and G4 (.000)
G1 and G3 (.000)
G2 and G4 (.023)
G2 and G3 (.017)
AUDIT 9.29 (7.40) 3.40 (4.97) 4.88 (4.65) 6.35 (7.31)
DUDIT 5.55 (8.04) .20 (.63) 4.04 (5.60) 4.58 (8.65)
CDSS-suicide .79 (.740) .36 (.505) .04 (.189) .02 (.135) G1 and G4 (.000)
G1 and G2 (.045)
G1 and G3 (.000)
PANSS Positive and negative syndrome scale.
GAF Global assessment of functioning.
PAS Premorbid adjustment scale.
DUP Duration of untreated psychosis.
AUDIT Alcohol use disorders identification test.
DUDIT Drug use disorders identification test.
CDSS Calgary depression scale for schizophrenia.
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Upthegrove and colleagues emphasizes how some pa-
tients with a psychotic disorder may be more vulnerable
to persistent depression. According to them, there may
be a depression that begins in adolescence, presents it-
self during the prodromal phase and re-emerges at fu-
ture times as a response to varied stressors [17]. This is
to some extent in line with the current findings in G1.
This group seems to be more vulnerable not only to de-
pression, but shows more global and overall psycho-
logical symptoms and has the lowest premorbid function
(childhood social, academic and early adolescent social).
Vulnerability to depression for this group may be partly
due to the severity of these symptoms. That this group did
not significantly differ from G2 and G3 in positive and
negative symptoms may indicate that depression in FEP is
not only intrinsic to psychotic symptoms, but also a reac-
tion to the more acute constraint of general and glo-
bal psychological symptoms which develop during the
psychotic episode.
To our knowledge, the present study is the first to
examine if baseline socio-demographic and clinical char-
acteristics predict depressive symptoms 12 months after
start of therapy. Patients with poor premorbid social func-
tioning in childhood, long duration of untreated psychosis
and depressive symptoms at baseline have more depres-
sive symptoms at 12 months follow-up. The group with
persistent depression (G1) had most global and psychotic
symptoms, as well as the highest suicide scores at both
baseline and follow-up. It is of great importance to
recognize such a group of FEP patients as early as pos-
sible, in order to provide a better prognosis and to prevent
depressive symptoms and suicidality. Riedel and col-
leagues [14] examined predictors of depression in the
acute phases of psychosis in patients treated with
risperidone and haloperidol. However, they did not, as in
the present study, examine patient characteristics that
could predict depressive symptoms after the acute phases
of the psychoses. Upthegrove and co-authors [17] found
that depressive symptoms in the acute phase of psychosis
predicted depressive symptoms at 12 months follow-up.
This is in line with the findings in our study. In addition,
we show that a long DUP and poor premorbid social func-
tioning in childhood predicts depressive symptoms at
12 months follow-up. Premorbid functioning has previ-
ously been associated with long term treatment outcome
[38-42] However, this is the first study that have showed
that premorbid functioning is important for the develop-
ment of depressive symptoms in FEP patients.
Limitations
Limitation of the study concern drop-out
The results in the present study could be influenced by
the relatively high drop-out rate (n = 71, 36%) from base-
line to 12 months follow-up. This represents loss of valu-
able information and may weaken the validity of the
findings. The patients who dropped out were most often
untraceable and did not respond to letters or phone calls.
Unfortunately, no additional information about reasons
for dropping out from the study was registered. However,
there were no significant differences at baseline between
those patients who dropped-out and the group who were
interviewed at 12 months follow-up as it comes to gender
distribution, age, symptoms and diagnostic distribution.
It could be argued that the results of the present study
are influenced by the overlap between negative symp-
toms and depressive symptoms. However, the present
study revealed no significant correlation between the
PANSS negative component scores and the CDSS total
Table 4 Blockwise multiple regression analysis of the relationship between baseline characteristics and CDSS total
score
B Standard error Significance Lower bound Upper bound Adjusted R square
Gender .703 .660 .289 -.603 .289 .009
PAS child. social .319 .118 .008* .085 .552
PAS child. academic .044 .142 .755 -.237 .325 .111
DUP .558 .181 .003* .198 .917 .171
PANSS positive -.057 .071 .420 -.198 .083
PANSS negative .039 .46 .397 -.053 .132
PANSS excitative -.248 .130 .060 -.506 .010
PANSS depressive .348 .093 .000** .165 .532
PANSS cognitive .046 .177 .797 -.305 .396 .251
Explained variance for final model: R2 =.305, F=5.608, P<.05.
*Significant at the P<.05 level.
**Significant at the P<.001 level.
PANSS Positive and negative syndrome scale.
PAS Premorbid adjustment scale.
DUP Duration of untreated psychosis.
CDSS Calgary depression scale for schizophrenia.
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scores at baseline and only a low but significant correl-
ation (0.18) between these two measures at 12 months
follow up. Even if we can not rule out an overlap be-
tween these negative and depressive symptoms, it would
probably have no major consequences for the results.
This study has not measured any qualitative aspects by
being depressed. The group of patients who were
continously depressed could have different reasons for be-
ing depressed at respectively baseline and 12 months fol-
low up. Factors like not being able to attend school or
work, might cause depressive symptoms just after the on-
set of psychotic symptoms. Furthermore, negative voices
putting the patients down, internal and external stigma
might cause depressive symptoms. These aspects and how
they are related to the course of depressive symptoms in
patients with psychosis should be explored in future stud-
ies. In the present study, we examined whether some of
the items comprising CDSS were scored differently at
baseline and 12 months follow up for the continously de-
pressed patients. No significant differences were found.
Conclusion
Depressive symptoms are frequent in FEP patients, both at
baseline and 12 months follow-up. Patient characteristics
such as premorbid social functioning, duration of untreated
psychosis and PANSS score of depression at baseline predict
depressive symptoms at 12 months follow-up. Patients with
different depressive symptoms trajectories differed on both
baseline socio-demographic and clinical characteristics.
These findings may be useful for improving identification
and management of depressive symptoms in FEP patients.
Study design
1) Prevalence of depressive symptoms in two different
measurement times; A baseline versus B 1-year.
2) Exploration of the course of depressive symptoms
during the 1-year follow-up.
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